The Epileptic Encephalopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Epileptic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Epileptic Encephalopathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Epileptic Encephalopathy and features dormant and discontinued products.
GlobalData tracks 31 drugs in development for Epileptic Encephalopathy by 21 companies/universities/institutes. The top development phase for Epileptic Encephalopathy is preclinical with 11 drugs in that stage. The Epileptic Encephalopathy pipeline has 30 drugs in development by companies and one by universities/ institutes. Some of the companies in the Epileptic Encephalopathy pipeline products market are: EpyGenix Therapeutics, Quiver Bioscience and Praxis Precision Medicines.
The key targets in the Epileptic Encephalopathy pipeline products market include Sodium Channel Protein Type 8 Subunit Alpha, Sodium Channel Protein Type 2 Subunit Alpha, and Potassium Voltage Gated Channel Subfamily KQT Member 2.
The key mechanisms of action in the Epileptic Encephalopathy pipeline product include Sodium Channel Protein Type 8 Subunit Alpha Blocker with three drugs in Phase II. The Epileptic Encephalopathy pipeline products include five routes of administration with the top ROA being Oral and four key molecule types in the Epileptic Encephalopathy pipeline products market including Small Molecule, and Antisense Oligonucleotide.
Epileptic Encephalopathy overview
Epileptic encephalopathies, characterized by epileptiform abnormalities and progressive cerebral dysfunction, present in eight age-related syndromes as per the International League Against Epilepsy. Neonatal syndromes include early myoclonic encephalopathy and Ohtahara syndrome, while infancy sees West syndrome and Dravet syndrome. Childhood and adolescence encompass myoclonic status, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, and epilepsy with continuous spike waves during slow wave sleep. Diagnosis entails EEG examination in both sleep and wake states, along with brain MRI to identify structural defects. Metabolic profiling checks for inherited metabolic issues. STXBP1 mutation testing is advised for Ohtahara syndrome. Treatment focuses on suppressing epileptiform discharges; drugs like valproate, benzodiazepines, levetiracetam, ethosuximide, and sulthiame have proven most effective.
For a complete picture of Epileptic Encephalopathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
